CD4+ T cells provide intermolecular help to generate robust antibody responses in vaccinia virus-vaccinated humans

Journal of Immunology

Volumn 190, Issue 12, 2013, Pages 6023-6033

  Yin, Liusong ^a   Calvo Calle, J Mauricio ^a   Cruz, John ^a   Newman, Frances K ^b   Frey, Sharon E ^b   Ennis, Francis A ^a   Stern, Lawrence J ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 2; VACCINIA VACCINE;

ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN RECOGNITION; ARTICLE; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; HUMAN; HUMAN EXPERIMENT; HUMORAL IMMUNITY; IMMUNOGENICITY; IMMUNOSTIMULATION; MOLECULAR INTERACTION; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; VACCINATION;

ANTIBODIES, VIRAL; CD4-POSITIVE T-LYMPHOCYTES; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; SMALLPOX; SMALLPOX VACCINE; VACCINATION; VACCINIA VIRUS; VIRAL ENVELOPE PROTEINS;

EID: 84879084356     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1202523     Document Type: Article

References (83)

1. Gerhard, W. 2001. The role of the antibody response in influenza virus infection. Curr. Top. Microbiol. Immunol. 260: 171-190. (Pubitemid 32574063)
2. Overbaugh, J., and L. Morris. 2012. The antibody response against HIV-1. Cold Spring Harb. Perspect. Med. 2: a007039.
3. Edghill-Smith, Y., H. Golding, J. Manischewitz, L. R. King, D. Scott, M. Bray, A. Nalca, J. W. Hooper, C. A. Whitehouse, J. E. Schmitz, et al. 2005. Smallpox vaccine-induced antibodies are necessary and sufficient for protection against monkeypox virus. Nat. Med. 11: 740-747. (Pubitemid 41021206)
4. Lustig, S., C. Fogg, J. C. Whitbeck, R. J. Eisenberg, G. H. Cohen, and B. Moss. 2005. Combinations of polyclonal or monoclonal antibodies to proteins of the outer membranes of the two infectious forms of vaccinia virus protect mice against a lethal respiratory challenge. J. Virol. 79: 13454-13462. (Pubitemid 41508158)
5. Zhang, G. Q., and J. E. Samuel. 2003. Identification and cloning potentially protective antigens of Coxiella burnetii using sera from mice experimentally infected with Nine Mile phase I. Ann. N. Y. Acad. Sci. 990: 510-520. (Pubitemid 36808354)
6. Xu, R., A. J. Johnson, D. Liggitt, and M. J. Bevan. 2004. Cellular and humoral immunity against vaccinia virus infection of mice. J. Immunol. 172: 6265-6271. (Pubitemid 38621233)
7. Amanna, I. J., M. K. Slifka, and S. Crotty. 2006. Immunity and immunological memory following smallpox vaccination. Immunol. Rev. 211: 320-337. (Pubitemid 43882983)
8. Kreijtz, J. H., R. A. Fouchier, and G. F. Rimmelzwaan. 2011. Immune responses to influenza virus infection. Virus Res. 162: 19-30.
9. Janeway, C. A., P. Travers, M. Walport, and M. J. Shlomchik. 2005. Immunology: The Immune System in Health and Disease. Garland Science, New York.
10. Russell, S. M., and F. Y. Liew. 1979. T cells primed by influenza virion internal components can cooperate in the antibody response to haemagglutinin. Nature 280: 147-148. (Pubitemid 9221740)
11. Scherle, P. A., and W. Gerhard. 1986. Functional analysis of influenza-specific helper T cell clones in vivo. T cells specific for internal viral proteins provide cognate help for B cell responses to hemagglutinin. J. Exp. Med. 164: 1114-1128. (Pubitemid 16031610)
12. Milich, D. R., A. McLachlan, G. B. Thornton, and J. L. Hughes. 1987. Antibody production to the nucleocapsid and envelope of the hepatitis B virus primed by a single synthetic T cell site. Nature 329: 547-549. (Pubitemid 17124776)
13. Esquivel, F. R., S. Lopez, L. Guitierrez-X, and C. Arias. 2000. The internal rotavirus protein VP6 primes for an enhanced neutralizing antibody response. Arch. Virol. 145: 813-825. (Pubitemid 30301844)
14. Shaw, D. M., C. M. Stanley, C. D. Partidos, and M. W. Steward. 1993. Influence of the T-helper epitope on the titre and affinity of antibodies to B-cell epitopes after co-immunization. Mol. Immunol. 30: 961-968.
15. Fatenejad, S., M. J. Mamula, and J. Craft. 1993. Role of intermolecular/intrastructural B- and T-cell determinants in the diversification of autoantibodies to ribonucleoprotein particles. Proc. Natl. Acad. Sci. USA 90: 12010-12014. (Pubitemid 24008770)
16. Scherle, P. A., and W. Gerhard. 1988. Differential ability of B cells specific for external vs. internal influenza virus proteins to respond to help from influenza virus-specific T-cell clones in vivo. Proc. Natl. Acad. Sci. USA 85: 4446-4450.
17. Oxenius, A., M. F. Bachmann, R. M. Zinkernagel, and H. Hengartner. 1998. Virus-specific MHC-class II-restricted TCR-transgenic mice: effects on humoral and cellular immune responses after viral infection. Eur. J. Immunol. 28: 390-400. (Pubitemid 28048309)
18. Goodman-Snitkoff, G., M. F. Good, J. A. Berzofsky, and R. J. Mannino. 1991. Role of intrastructural/intermolecular help in immunization with peptide-phospholipid complexes. J. Immunol. 147: 410-415.
19. Sette, A., M. Moutaftsi, J. Moyron-Quiroz, M. M. McCausland, D. H. Davies, R. J. Johnston, B. Peters, M. Rafii-El-Idrissi Benhnia, J. Hoffmann, H. P. Su, et al. 2008. Selective CD4+ T cell help for antibody responses to a large viral pathogen: deterministic linkage of specificities. Immunity 28: 847-858. (Pubitemid 351778408)
20. Moutaftsi, M., H. H. Bui, B. Peters, J. Sidney, S. Salek-Ardakani, C. Oseroff, V. Pasquetto, S. Crotty, M. Croft, E. J. Lefkowitz, et al. 2007. Vaccinia virus-specific CD4+ T cell responses target a set of antigens largely distinct from those targeted by CD8+ T cell responses. J. Immunol. 178: 6814-6820. (Pubitemid 46847406)
21. Condit, R. C., N. Moussatche, and P. Traktman. 2006. In a nutshell: structure and assembly of the vaccinia virion. Adv. Virus Res. 66: 31-124. (Pubitemid 44131526)
22. Roberts, K. L., and G. L. Smith. 2008. Vaccinia virus morphogenesis and dissemination. Trends Microbiol. 16: 472-479.
23. Goldstein, J. L., R. G. Anderson, and M. S. Brown. 1979. Coated pits, coated vesicles, and receptor-mediated endocytosis. Nature 279: 679-685. (Pubitemid 9205224)
24. West, M. A., J. M. Lucocq, and C. Watts. 1994. Antigen processing and class II MHC peptide-loading compartments in human B-lymphoblastoid cells. Nature 369: 147-151. (Pubitemid 24153437)
25. Lodish, H., A. Berk, P. Matsudaira, C. Kaiser, M. Krieger, M. Scott, L. Zipursky, and J. Darnell. 2003. Molecular Cell Biology. W.H. Freeman, New York.
26. Cyster, J. G. 2010. B cell follicles and antigen encounters of the third kind. Nat. Immunol. 11: 989-996.
27. Nayak, J. L., T. F. Fitzgerald, K. A. Richards, H. Yang, J. J. Treanor, and A. J. Sant. 2013. CD4+ T-cell expansion predicts neutralizing antibody responses to monovalent, inactivated 2009 pandemic influenza A(H1N1) virus subtype H1N1 vaccine. J. Infect. Dis. 207: 297-305.
28. Haynes, L., F. M. Szaba, S. M. Eaton, L. W. Kummer, P. A. Lanthier, A. H. Petell, D. K. Duso, D. Luo, J. S. Lin, J. S. Lefebvre, et al. 2012. Immunity to the conserved influenza nucleoprotein reduces susceptibility to secondary bacterial infections. J. Immunol. 189: 4921-4929.
29. Snapper, C. M. 2012. Mechanisms underlying in vivo polysaccharide- specific immunoglobulin responses to intact extracellular bacteria. Ann. N. Y. Acad. Sci. 1253: 92-101.
30. Catron, D. M., K. A. Pape, B. T. Fife, N. van Rooijen, and M. K. Jenkins. 2010. A protease-dependent mechanism for initiating T-dependent B cell responses to large particulate antigens. J. Immunol. 184: 3609-3617.
31. Jørgensen, K. W., S. Buus, and M. Nielsen. 2010. Structural properties of MHC class II ligands, implications for the prediction of MHC class II epitopes. PLoS ONE 5: e15877.
32. Batista, F. D., and N. E. Harwood. 2009. The who, how and where of antigen presentation to B cells. Nat. Rev. Immunol. 9: 15-27.
33. Nayak, J. L., K. A. Richards, F. A. Chaves, and A. J. Sant. 2010. Analyses of the specificity of CD4 T cells during the primary immune response to influenza virus reveals dramatic MHC-linked asymmetries in reactivity to individual viral proteins. Viral Immunol. 23: 169-180.
34. Richards, K. A., D. Topham, F. A. Chaves, and A. J. Sant. 2010. Cutting edge: CD4 T cells generated from encounter with seasonal influenza viruses and vaccines have broad protein specificity and can directly recognize naturally generated epitopes derived from the live pandemic H1N1 virus. J. Immunol. 185: 4998-5002.
35. Judkowski, V., A. Bunying, F. Ge, J. R. Appel, K. Law, A. Sharma, C. Raja-Gabaglia, P. Norori, R. G. Santos, M. A. Giulianotti, et al. 2011. GM-CSF production allows the identification of immunoprevalent antigens recognized by human CD4+ T cells following smallpox vaccination. PLoS ONE 6: e24091.
36. Kennedy, R. B., and G. A. Poland. 2010. The identification of HLA class II-restricted T cell epitopes to vaccinia virus membrane proteins. Virology 408: 232-240.
37. Valentino, M. D., Z. J. Maben, L. L. Hensley, M. D. Woolard, T. H. Kawula, J. A. Frelinger, and J. G. Frelinger. 2011. Identification of T-cell epitopes in Francisella tularensis using an ordered protein array of serological targets. Immunology 132: 348-360.
38. Oseroff, C., J. Sidney, M. F. Kotturi, R. Kolla, R. Alam, D. H. Broide, S. I. Wasserman, D. Weiskopf, D. M. McKinney, J. L. Chung, et al. 2010. Molecular determinants of T cell epitope recognition to the common Timothy grass allergen. J. Immunol. 185: 943-955.
39. Homan, E. J., and R. D. Bremel. 2011. Patterns of predicted T-cell epitopes associated with antigenic drift in influenza H3N2 hemagglutinin. PLoS ONE 6: e26711.
40. Burton, D. R., R. Ahmed, D. H. Barouch, S. T. Butera, S. Crotty, A. Godzik, D. E. Kaufmann, M. J. McElrath, M. C. Nussenzweig, B. Pulendran, et al. 2012. A blueprint for HIV vaccine discovery. Cell Host Microbe 12: 396-407.
41. van Houten, N. E., K. A. Henry, G. P. Smith, and J. K. Scott. 2010. Engineering filamentous phage carriers to improve focusing of antibody responses against peptides. Vaccine 28: 2174-2185.
42. + T cells in immunity to viruses. Nat. Rev. Immunol. 12: 136-148.
43. Stern, L. J., and J. M. Calvo-Calle. 2009. HLA-DR: molecular insights and vaccine design. Curr. Pharm. Des. 15: 3249-3261.
44. Kennedy, R. B., I. G. Ovsyannikova, R. M. Jacobson, and G. A. Poland. 2009. The immunology of smallpox vaccines. Curr. Opin. Immunol. 21: 314-320.
45. Richards, K. A., F. A. Chaves, and A. J. Sant. 2009. Infection of HLA-DR1 transgenic mice with a human isolate of influenza a virus (H1N1) primes a diverse CD4 T-cell repertoire that includes CD4 T cells with heterosubtypic cross-reactivity to avian (H5N1) influenza virus. J. Virol. 83: 6566-6577.
46. Chen, C., C. Dow, P. Wang, J. Sidney, A. Read, A. Harmsen, J. E. Samuel, and B. Peters. 2011. Identification of CD4+ T cell epitopes in C. burnetii antigens targeted by antibody responses. PLoS ONE 6: e17712.
47. Calvo-Calle, J. M., I. Strug, M. D. Nastke, S. P. Baker, and L. J. Stern. 2007. Human CD4+ T cell epitopes from vaccinia virus induced by vaccination or infection. PLoS Pathog. 3: 1511-1529. (Pubitemid 350085615)
48. Jing, L., D. H. Davies, T. M. Chong, S. Chun, C. L. McClurkan, J. Huang, B. T. Story, D. M. Molina, S. Hirst, P. L. Felgner, and D. M. Koelle. 2008. An extremely diverse CD4 response to vaccinia virus in humans is revealed by proteome-wide T-cell profiling. J. Virol. 82: 7120-7134. (Pubitemid 351977730)
49. Jing, L., T. M. Chong, B. Byrd, C. L. McClurkan, J. Huang, B. T. Story, K. M. Dunkley, L. Aldaz-Carroll, R. J. Eisenberg, G. H. Cohen, et al. 2007. Dominance and diversity in the primary human CD4 T cell response to replication-competent vaccinia virus. J. Immunol. 178: 6374-6386. (Pubitemid 46717422)
50. Davies, D. H., X. Liang, J. E. Hernandez, A. Randall, S. Hirst, Y. Mu, K. M. Romero, T. T. Nguyen, M. Kalantari-Dehaghi, S. Crotty, et al. 2005. Profiling the humoral immune response to infection by using proteome microarrays: high-throughput vaccine and diagnostic antigen discovery. Proc. Natl. Acad. Sci. USA 102: 547-552. (Pubitemid 40282702)
51. Duke-Cohan, J. S., K. Wollenick, E. A. Witten, M. S. Seaman, L. R. Baden, R. Dolin, and E. L. Reinherz. 2009. The heterogeneity of human antibody responses to vaccinia virus revealed through use of focused protein arrays. Vaccine 27: 1154-1165.
52. Hooper, J. W., D. M. Custer, and E. Thompson. 2003. Four-gene-combination DNA vaccine protects mice against a lethal vaccinia virus challenge and elicits appropriate antibody responses in nonhuman primates. Virology 306: 181-195. (Pubitemid 36293408)
53. Hooper, J. W., E. Thompson, C. Wilhelmsen, M. Zimmerman, M. A. Ichou, S. E. Steffen, C. S. Schmaljohn, A. L. Schmaljohn, and P. B. Jahrling. 2004. Smallpox DNA vaccine protects nonhuman primates against lethal monkeypox. J. Virol. 78: 4433-4443. (Pubitemid 38501063)
54. Heraud, J. M., Y. Edghill-Smith, V. Ayala, I. Kalisz, J. Parrino, V. S. Kalyanaraman, J. Manischewitz, L. R. King, A. Hryniewicz, C. J. Trindade, et al. 2006. Subunit recombinant vaccine protects against monkeypox. J. Immunol. 177: 2552-2564. (Pubitemid 44201014)
55. Fogg, C., S. Lustig, J. C. Whitbeck, R. J. Eisenberg, G. H. Cohen, and B. Moss. 2004. Protective immunity to vaccinia virus induced by vaccination with multiple recombinant outer membrane proteins of intracellular and extracellular virions. J. Virol. 78: 10230-10237. (Pubitemid 39258347)
56. Pütz, M. M., C. M. Midgley, M. Law, and G. L. Smith. 2006. Quantification of antibody responses against multiple antigens of the two infectious forms of Vaccinia virus provides a benchmark for smallpox vaccination. Nat. Med. 12: 1310-1315. (Pubitemid 44706934)
57. Sirven, P., F. A. Castelli, A. Probst, N. Szely, and B. Maillere. 2009. In vitro human CD4+ T cell response to the vaccinia protective antigens B5R and A33R. Mol. Immunol. 46: 1481-1487.
58. Frey, S. E., F. K. Newman, J. S. Kennedy, F. Ennis, G. Abate, D. F. Hoft, and T. P. Monath. 2009. Comparison of the safety and immunogenicity of ACAM1000, ACAM2000 and Dryvax in healthy vaccinia-naive adults. Vaccine 27: 1637-1644.
59. Weltzin, R., J. Liu, K. V. Pugachev, G. A. Myers, B. Coughlin, P. S. Blum, R. Nichols, C. Johnson, J. Cruz, J. S. Kennedy, et al. 2003. Clonal vaccinia virus grown in cell culture as a new smallpox vaccine. Nat. Med. 9: 1125-1130. (Pubitemid 37173695)
60. Monath, T. P., J. R. Caldwell, W. Mundt, J. Fusco, C. S. Johnson, M. Buller, J. Liu, B. Gardner, G. Downing, P. S. Blum, et al. 2004. ACAM2000 clonal Vero cell culture vaccinia virus (New York City Board of Health strain) - a second-generation smallpox vaccine for biological defense. Int. J. Infect. Dis. 8(Suppl. 2): S31-S44. (Pubitemid 39445966)
61. Tang, J., M. Murtadha, M. Schnell, L. C. Eisenlohr, J. Hooper, and P. Flomenberg. 2006. Human T-cell responses to vaccinia virus envelope proteins. J. Virol. 80: 10010-10020. (Pubitemid 44522595)
62. Oseroff, C., F. Kos, H. H. Bui, B. Peters, V. Pasquetto, J. Glenn, T. Palmore, J. Sidney, D. C. Tscharke, J. R. Bennink, et al. 2005. HLA class I-restricted responses to vaccinia recognize a broad array of proteins mainly involved in virulence and viral gene regulation. Proc. Natl. Acad. Sci. USA 102: 13980-13985. (Pubitemid 41377689)
63. Terajima, M., L. Orphin, A. M. Leporati, P. Pazoles, J. Cruz, A. L. Rothman, and F. A. Ennis. 2008. Vaccinia virus-specific CD8(+) T-cell responses target a group of epitopes without a strong immunodominance hierarchy in humans. Hum. Immunol. 69: 815-825.
64. Lazarski, C. A., F. A. Chaves, S. A. Jenks, S. Wu, K. A. Richards, J. M. Weaver, and A. J. Sant. 2005. The kinetic stability of MHC class II:peptide complexes is a key parameter that dictates immunodominance. Immunity 23: 29-40. (Pubitemid 41019655)
65. Lazarski, C. A., F. A. Chaves, and A. J. Sant. 2006. The impact of DM on MHC class II-restricted antigen presentation can be altered by manipulation of MHC-peptide kinetic stability. J. Exp. Med. 203: 1319-1328. (Pubitemid 43736600)
66. Roos, N., M. Cyrklaff, S. Cudmore, R. Blasco, J. Krijnse-Locker, and G. Griffiths. 1996. A novel immunogold cryoelectron microscopic approach to investigate the structure of the intracellular and extracellular forms of vaccinia virus. EMBO J. 15: 2343-2355. (Pubitemid 26151175)
67. Crotty, S., P. Felgner, H. Davies, J. Glidewell, L. Villarreal, and R. Ahmed. 2003. Cutting edge: long-term B cell memory in humans after smallpox vaccination. J. Immunol. 171: 4969-4973. (Pubitemid 37432774)
68. Hammarlund, E., M. W. Lewis, S. G. Hansen, L. I. Strelow, J. A. Nelson, G. J. Sexton, J. M. Hanifin, and M. K. Slifka. 2003. Duration of antiviral immunity after smallpox vaccination. Nat. Med. 9: 1131-1137. (Pubitemid 37173696)
69. Galmiche, M. C., J. Goenaga, R. Wittek, and L. Rindisbacher. 1999. Neutralizing and protective antibodies directed against vaccinia virus envelope antigens. Virology 254: 71-80. (Pubitemid 29391715)
70. Law, M., and G. L. Smith. 2001. Antibody neutralization of the extracellular enveloped form of vaccinia virus. Virology 280: 132-142. (Pubitemid 34158059)
71. Bell, E., M. Shamim, J. C. Whitbeck, G. Sfyroera, J. D. Lambris, and S. N. Isaacs. 2004. Antibodies against the extracellular enveloped virus B5R protein are mainly responsible for the EEV neutralizing capacity of vaccinia immune globulin. Virology 325: 425-431. (Pubitemid 38902805)
72. Henderson, D. A., T. V. Inglesby, J. G. Bartlett, M. S. Ascher, E. Eitzen, P. B. Jahrling, J. Hauer, M. Layton, J. McDade, M. T. Osterholm, et al Working Group on Civilian Biodefense. 1999. Smallpox as a biological weapon: medical and public health management. JAMA 281: 2127-2137. (Pubitemid 29264692)
73. Carroll, M. W., and B. Moss. 1997. Poxviruses as expression vectors. Curr. Opin. Biotechnol. 8: 573-577. (Pubitemid 27455333)
74. Gómez, C. E., B. Perdiguero, J. L. Nájera, C. O. Sorzano, V. Jiménez, R. González-Sanz, and M. Esteban. 2012. Removal of vaccinia virus genes that block interferon type I and II pathways improves adaptive and memory responses of the HIV/AIDS vaccine candidate NYVAC-C in mice. J. Virol. 86: 5026-5038.
75. Jones, B. G., R. E. Sealy, X. Zhan, P. J. Freiden, S. L. Surman, J. L. Blanchard, and J. L. Hurwitz. 2012. UV-inactivated vaccinia virus (VV) in a multi-envelope DNA-VV-protein (DVP) HIV-1 vaccine protects macaques from lethal challenge with heterologous SHIV. Vaccine 30: 3188-3195.
76. Shen, Y., and J. Nemunaitis. 2005. Fighting cancer with vaccinia virus: teaching new tricks to an old dog. Mol. Ther. 11: 180-195. (Pubitemid 40163961)
77. John, L. B., L. J. Howland, J. K. Flynn, A. C. West, C. Devaud, C. P. Duong, T. J. Stewart, J. A. Westwood, Z. S. Guo, D. L. Bartlett, et al. 2012. Oncolytic virus and anti-4-1BB combination therapy elicits strong antitumor immunity against established cancer. Cancer Res. 72: 1651-1660.
78. Carter, G. C., M. Law, M. Hollinshead, and G. L. Smith. 2005. Entry of the vaccinia virus intracellular mature virion and its interactions with glycosaminoglycans. J. Gen. Virol. 86: 1279-1290. (Pubitemid 40613244)
79. Law, M., G. C. Carter, K. L. Roberts, M. Hollinshead, and G. L. Smith. 2006. Ligand-induced and nonfusogenic dissolution of a viral membrane. Proc. Natl. Acad. Sci. USA 103: 5989-5994.
80. Mercer, J., and A. Helenius. 2008. Vaccinia virus uses macropinocytosis and apoptotic mimicry to enter host cells. Science 320: 531-535. (Pubitemid 351590666)
81. Schmidt, F. I., C. K. Bleck, A. Helenius, and J. Mercer. 2011. Vaccinia extracellular virions enter cells by macropinocytosis and acid-activated membrane rupture. EMBO J. 30: 3647-3661.
82. Junt, T., E. A. Moseman, M. Iannacone, S. Massberg, P. A. Lang, M. Boes, K. Fink, S. E. Henrickson, D. M. Shayakhmetov, N. C. Di Paolo, et al. 2007. Subcapsular sinus macrophages in lymph nodes clear lymph-borne viruses and present them to antiviral B cells. Nature 450: 110-114. (Pubitemid 350070574)
83. Yewdell, J. W. 2006. Confronting complexity: real-world immunodominance in antiviral CD8+ T cell responses. Immunity 25: 533-543. (Pubitemid 44529047)